ADVFN US – Market Content Editor
-
Benchmark Ups Tesla Price Target to $475 Following Robotaxi Debut in Austin
Benchmark has raised its price target for Tesla (NASDAQ:TSLA) to $475, up from a previous estimate of $350, citing the promising rollout of the company’s robotaxi pilot in Austin, Texas. According to analyst Mickey Legg, the pilot’s limited scope reflects a “measured and safety-driven strategy” that could enhance public and regulatory confidence in Tesla’s autonomous…
-
Dow Jones, S&P, Nasdaq, Futures Point To Positive Wall Street Open
U.S. equity futures signaled a positive open on Thursday, buoyed by a series of stronger-than-expected economic reports that lifted sentiment despite recent volatility and mixed prior session results. Weekly jobless claims data surprised to the downside, with the Labor Department reporting a decline to 236,000 for the week ending June 21. This was 10,000 fewer…
-
First-Time U.S. Unemployment Benefit Claims Down Unexpectedly
A report released by the Labor Department on Thursday showed first-time claims for U.S. unemployment benefits unexpectedly fell in the week ended June 21st. The Labor Department said initial jobless claims dipped to 236,000, a decrease of 10,000 from the previous week’s revised level of 246,000. Economists had expected jobless claims to come in unchanged…
-
Kewaunee Scientific Shares Jump 23.5% Following Strong Q4 Earnings Report
Kewaunee Scientific Corporation (NASDAQ:KEQU) delivered a robust finish to its fiscal year, posting fourth-quarter results that far outpaced the prior year and sparked a 23.5% surge in after-hours trading. For the quarter ending April 30, 2025, the laboratory equipment and furniture manufacturer reported adjusted earnings per share of $1.95, while revenue climbed 36.1% year-over-year to…
-
Lindsay Tops Q3 Estimates on Robust Global Irrigation Demand
Lindsay Corporation (NYSE:LNN) exceeded Wall Street expectations for its fiscal third quarter, fueled by a sharp increase in international irrigation sales. The strong results lifted the company’s stock nearly 2% in pre-market trading. The irrigation technology provider reported adjusted earnings of $1.78 per share, well ahead of the $1.41 consensus estimate, while quarterly revenue reached…
-
Incyte Shares Gain Following Appointment of New CEO Bill Meury
Shares of Incyte Corporation (NASDAQ:INCY) rose 3.6% on Thursday after the biopharmaceutical firm named Bill Meury as its new President and Chief Executive Officer, effective immediately. Meury, a seasoned executive with more than 30 years in the pharmaceutical industry, takes over from Hervé Hoppenot, who is retiring after over a decade at the company’s helm.…
-
Cyngn Shares Skyrocket After NVIDIA Highlights Its Autonomous Tech
Shares of Cyngn Inc. (NASDAQ:CYN) surged over 130% after the company received a prominent mention in a NVIDIA (NASDAQ:NVDA) blog post, spotlighting its role in the development of autonomous industrial vehicles. The blog, which focused on robotics firms leveraging NVIDIA’s Isaac platform, featured Cyngn as one of the innovators using the technology to build advanced…
-
Walgreens Tops Q3 Estimates Ahead of $10B Privatization Deal
Walgreens Boots Alliance (NASDAQ:WBA) reported stronger-than-expected earnings and revenue for its fiscal third quarter, as cost-cutting measures helped offset weakness in front-of-store sales. The upbeat results come as the company prepares to transition from a public to private entity. The U.S.’s second-largest pharmacy chain is in the midst of a $10 billion buyout agreement with…
-
Altimmune Shares Slide 37% Despite Hitting Key MASH Trial Goals
Altimmune Inc. (NASDAQ:ALT) saw its stock tumble by 37% after releasing topline data from its Phase 2b IMPACT trial evaluating pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The biopharmaceutical company reported that the trial met its primary goal—up to 59.1% of patients achieved resolution of MASH without worsening fibrosis based on an intent-to-treat…
-
Pfizer Reports Breakthrough Phase 3 Results for Hemophilia Therapy
Pfizer Inc. (NYSE:PFE) announced encouraging results from its Phase 3 clinical trial of HYMPAVZI, a potential new treatment for patients with hemophilia A or B who develop inhibitors—a major complication that limits the effectiveness of standard therapies. The company stated that HYMPAVZI outperformed existing treatments, achieving a 93% reduction in annualized bleeding rates among trial…